Skip to main content
Premium Trial:

Request an Annual Quote

Revenues Flat, Net Losses Balloon at Luminex in Q1

Luminex's net loss for the first quarter increased to $298,000 from $143,000 year over year, not to $298 million from $143 million. The company's research and development expenses increased from 958,000 to $1 million, not $958 million to $1 billion.

NEW YORK, April 28 (GenomeWeb News) -
Flat revenues and a surge in net loss greeted Luminex investors at the end of the first quarter of 2005, according to documents filed yesterday with the US Securities and Exchange Commission.


The Austin, Tex.-based company reported revenues of $9.3 million for the period ended March 31, 2005, a rise of $25,000 over first-quarter 2004 revenues.


Net loss for the recent period grew 48 percent to $298,000 from $143,000 year over year. Per-share net loss for the first quarter of 2005 was $.01, and $.00 for the first quarter of 2004.


The company invested an additional $59,000 in research and development, reporting expenses in that category of $1 million in the current quarter of 2005, compared to $958,000 in the similar quarter of 2004.


Cash and cash equivalents on hand at the end of the recent quarter amounted to $14.3 million.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.